生物信息技术在脑肿瘤病因学中的应用
发布时间：2019-07-02 18:28
【摘要】：第一部分生物信息学技术在脑胶质瘤病因学中的应用 目的探讨饮酒、染发、ERCC1C8092A多态性、外源性的雌孕激素的使用、生殖因素与胶质瘤发病风险关系。 方法提取PubMed和Embase数据库中有关饮酒、染发、ERCC1C8092A多态性、外源性的雌孕激素的使用、生殖因素与胶质瘤发病风险的数据，筛选出符合纳入标准的研究。应用Meta分析技术和Stata11.0软件对所提取的数据进行合并分析、异质性分析、亚组分析、敏感性分析、发表偏移检测。 结果共38个研究纳入此次分析。Meta分析结果显示使用口服避孕药(RR=0.71,95%CI=0.60-0.83)及绝经期雌孕激素替代治疗(RR=0.68,95%CI=0.58-0.81)能降低胶质瘤发病风险；ERCC1C8092A的AA基因型(OR=1.23,95%CI=1.01-1.51)及月经初潮的年龄(RR=1.40,95%CI=1.05-1.87)能增加胶质瘤发病风险；月经状态(RR=0.96,95%CI=0.67-1.37)、生育状态(RR=0.84,95%CI=0.67-1.04)、绝经的年龄(RR=0.97,95%CI=0.78-1.21)、第一次生育的年龄(RR=1.15,95%CI=0.88-1.51)、饮酒(RR=0.96,95%CI=0.89-1.04)及染发(RR=1.13,95%CI=0.89-1.45)与胶质瘤发病风险无显著相关性。 结论ERCC1C8092A多态性能增加胶质瘤的发病风险。口服避孕药，雌孕激素替代治疗可降低胶质瘤发病风险。与月经初潮年龄小的女性相比，月经初潮年龄大的女性具有更高胶质瘤发病风险。 第二部分生物信息学技术在脑膜瘤病因学中的应用 目的探讨体重指数、外源性的雌孕激素的使用、生殖因素与脑膜瘤发病风险关系。 方法提取PubMed和Embase数据库中有关体重指数、外源性的雌孕激素的使用、生殖因素与脑膜瘤发病风险的数据，，筛选出符合纳入标准的研究。应用Meta分析技术和Stata11.0软件对所提取的数据进行合并分析、异质性分析、亚组分析、敏感性分析、发表偏移检测。 结果共20个研究纳入此次分析。Meta分析结果显示绝经期雌孕激素替代治疗(RR=1.19,95%CI=1.01-1.40)、绝经(RR=1.32,95%CI=1.07-1.64)、生育次数(RR=1.18,95%CI=1.00-1.40)、肥胖(RR=1.45,95%CI=1.26-1.67)能增加脑膜瘤的发病风险；口服避孕药(RR=0.93,95%CI=0.83-1.03)、月经初潮的年龄(RR=1.06,95%CI=0.92-1.21)、绝经的年龄(RR=1.03,95%CI=0.81-1.30)、第一次生育的年龄(RR=0.94,95%CI=0.80-1.10)及超重(RR=1.12,95%CI=0.98-1.28)与脑膜瘤发病风险无显著相关性。 结论雌孕激素替代治疗、绝经、生育次数、肥胖能增加脑膜瘤发病风险。
[Abstract]:Part 1 Application of bioinformatics in the etiology of glioma objective to investigate the relationship between drinking, hair staining, ERCC1C8092A polymorphism, the use of exogenous estrogen and progesterone, reproductive factors and the risk of glioma. Methods the data of drinking, hair staining, ERCC1C8092A polymorphism, the use of exogenous estrogen and progesterone, reproductive factors and the risk of glioma were extracted from PubMed and Embase databases, and the studies that met the inclusion criteria were screened out. Meta analysis technique and Stata11.0 software were used to analyze the extracted data, heterogeneity analysis, subgroup analysis, sensitivity analysis and published migration detection. Results A total of 38 studies were included in the analysis. Meta-analysis showed that oral contraceptive (RR=0.71,95%CI=0.60-0.83) and menopausal estrogen replacement therapy (RR=0.68,95%CI=0.58-0.81) could reduce the risk of glioma, and the AA genotype (OR=1.23,95%CI=1.01-1.51) of ERCC1C8092A and the age of menarche (RR=1.40,95%CI=1.05-1.87) could increase the risk of glioma. Menstrual status (RR=0.96,95%CI=0.67-1.37), fertility status (RR=0.84,95%CI=0.67-1.04), age of menopause (RR=0.97,95%CI=0.78-1.21), age of first birth (RR=1.15,95%CI=0.88-1.51), drinking (RR=0.96,95%CI=0.89-1.04) and hair dye (RR=1.13,95%CI=0.89-1.45) were not significantly correlated with the risk of glioma. Conclusion the polymorphism of ERCC1C8092A increases the risk of glioma. Oral contraceptive and estrogen and progesterone replacement therapy can reduce the risk of glioma. Women with older menarche have a higher risk of glioma than women with younger menarche. Part II Application of bioinformatics in meningioma objective to investigate the relationship between body mass index (BMI), the use of exogenous estrogen and progesterone, reproductive factors and the risk of meningioma. Methods the data of body mass index (BMI), the use of exogenous estrogen and progesterone, reproductive factors and the risk of meningioma were extracted from PubMed and Embase databases, and the studies that met the inclusion criteria were screened out. Meta analysis technique and Stata11.0 software were used to analyze the extracted data, heterogeneity analysis, subgroup analysis, sensitivity analysis and published migration detection. Results A total of 20 studies were included in the analysis. Meta-analysis showed that estrogen replacement therapy (RR=1.19,95%CI=1.01-1.40), menopause (RR=1.32,95%CI=1.07-1.64), fertility frequency (RR=1.18,95%CI=1.00-1.40) and obesity (RR=1.45,95%CI=1.26-1.67) increased the risk of meningioma. Oral contraceptive (RR=0.93,95%CI=0.83-1.03), menarche age (RR=1.06,95%CI=0.92-1.21), menopausal age (RR=1.03,95%CI=0.81-1.30), age of first birth (RR=0.94,95%CI=0.80-1.10) and overweight (RR=1.12,95%CI=0.98-1.28) were not significantly correlated with the risk of meningioma. Conclusion estrogen and progesterone replacement therapy, menopausal, fertility and obesity can increase the risk of meningioma.
【学位授予单位】：苏州大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R739.41
本文编号：2509137
[Abstract]:Part 1 Application of bioinformatics in the etiology of glioma objective to investigate the relationship between drinking, hair staining, ERCC1C8092A polymorphism, the use of exogenous estrogen and progesterone, reproductive factors and the risk of glioma. Methods the data of drinking, hair staining, ERCC1C8092A polymorphism, the use of exogenous estrogen and progesterone, reproductive factors and the risk of glioma were extracted from PubMed and Embase databases, and the studies that met the inclusion criteria were screened out. Meta analysis technique and Stata11.0 software were used to analyze the extracted data, heterogeneity analysis, subgroup analysis, sensitivity analysis and published migration detection. Results A total of 38 studies were included in the analysis. Meta-analysis showed that oral contraceptive (RR=0.71,95%CI=0.60-0.83) and menopausal estrogen replacement therapy (RR=0.68,95%CI=0.58-0.81) could reduce the risk of glioma, and the AA genotype (OR=1.23,95%CI=1.01-1.51) of ERCC1C8092A and the age of menarche (RR=1.40,95%CI=1.05-1.87) could increase the risk of glioma. Menstrual status (RR=0.96,95%CI=0.67-1.37), fertility status (RR=0.84,95%CI=0.67-1.04), age of menopause (RR=0.97,95%CI=0.78-1.21), age of first birth (RR=1.15,95%CI=0.88-1.51), drinking (RR=0.96,95%CI=0.89-1.04) and hair dye (RR=1.13,95%CI=0.89-1.45) were not significantly correlated with the risk of glioma. Conclusion the polymorphism of ERCC1C8092A increases the risk of glioma. Oral contraceptive and estrogen and progesterone replacement therapy can reduce the risk of glioma. Women with older menarche have a higher risk of glioma than women with younger menarche. Part II Application of bioinformatics in meningioma objective to investigate the relationship between body mass index (BMI), the use of exogenous estrogen and progesterone, reproductive factors and the risk of meningioma. Methods the data of body mass index (BMI), the use of exogenous estrogen and progesterone, reproductive factors and the risk of meningioma were extracted from PubMed and Embase databases, and the studies that met the inclusion criteria were screened out. Meta analysis technique and Stata11.0 software were used to analyze the extracted data, heterogeneity analysis, subgroup analysis, sensitivity analysis and published migration detection. Results A total of 20 studies were included in the analysis. Meta-analysis showed that estrogen replacement therapy (RR=1.19,95%CI=1.01-1.40), menopause (RR=1.32,95%CI=1.07-1.64), fertility frequency (RR=1.18,95%CI=1.00-1.40) and obesity (RR=1.45,95%CI=1.26-1.67) increased the risk of meningioma. Oral contraceptive (RR=0.93,95%CI=0.83-1.03), menarche age (RR=1.06,95%CI=0.92-1.21), menopausal age (RR=1.03,95%CI=0.81-1.30), age of first birth (RR=0.94,95%CI=0.80-1.10) and overweight (RR=1.12,95%CI=0.98-1.28) were not significantly correlated with the risk of meningioma. Conclusion estrogen and progesterone replacement therapy, menopausal, fertility and obesity can increase the risk of meningioma.
【学位授予单位】：苏州大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R739.41
【参考文献】
相关期刊论文 前3条
1 程新;黄林;李昆太;;Meta分析:一种新的文献综述方法[J];广东农业科学;2010年06期
2 赵春霞,石先哲,吕申,马坚妹,杨青,许国旺;人类基因组的单核苷酸多态性及其研究进展[J];色谱;2003年02期
3 罗怀容,施鹏,张亚平;单核苷酸多态性的研究技术[J];遗传;2001年05期
本文编号：2509137
本文链接：https://www.wllwen.com/yixuelunwen/shenjingyixue/2509137.html
最近更新
教材专著
